甲亢治疗后肥胖风险增加:大型前瞻性二级保健队列研究
该研究比较1373例显性甲亢患者与年龄性别匹配的背景人群,发现治疗期间男性体重增加8.0 kg、女性5.5 kg,出院时肥胖风险显著增加(男性OR=1.7,女性OR=1.3)。131I治疗及后续甲减与额外体重增加相关,提示甲亢治疗存在体重「 overshoot」风险。
要点
- 甲亢治疗后肥胖风险显著高于背景人群,男性OR=1.7,女性OR=1.3。
- 治疗期间男性体重增加8.0 kg,女性增加5.5 kg。
- 131I治疗及甲减与额外体重增加相关,需个体化权衡。
核心结论
- 甲亢治疗与显著增加的肥胖风险相关。
- 131I治疗及后续甲减相比单用ATD与少量但显著的额外体重增加相关。
研究设计与样本
- 前瞻性二级保健队列研究,纳入1373例显性甲亢患者,与年龄性别匹配的背景人群(Health Survey for England 2007-2009)比较BMI。
主要发现
- 治疗期间男性体重增加8.0 kg(标准差±7.5),女性增加5.5 kg(±6.8)。
- 出院时甲亢患者肥胖风险显著增加:男性OR=1.7(95%CI 1.3-2.2,p<0.001),女性OR=1.3(95%CI 1.2-1.5,p<0.001)。
- 131I治疗相比单用ATD与额外体重增加0.6 kg(95%CI 0.4-0.8,p<0.001)相关。
- 随访期间TSH>10 mIU/L与额外体重增加0.5 kg(95%CI 0.3-0.7,p<0.001)相关,fT4≤10 pmol/L(0.8 ng/dL)与额外体重增加0.3 kg(95%CI 0.1-0.4,p<0.001)相关。
- 启动左甲状腺素治疗与额外体重增加0.4 kg(95%CI 0.2-0.6,p<0.001)相关,131I诱导甲减的预测额外体重增加为1.8 kg。
关键数值与推荐
- 肥胖定义为BMI>30 kg/m2。
- 甲亢治疗后男性肥胖OR=1.7(95%CI 1.3-2.2,p<0.001),女性OR=1.3(95%CI 1.2-1.5,p<0.001)。
- 131I治疗相比ATD单用额外体重增加0.6 kg(95%CI 0.4-0.8,p<0.001)。
- TSH>10 mIU/L时额外体重增加0.5 kg(95%CI 0.3-0.7,p<0.001)。
- fT4≤10 pmol/L(0.8 ng/dL)时额外体重增加0.3 kg(95%CI 0.1-0.4,p<0.001)。
临床怎么用
- 甲亢治疗决策时应个体化讨论体重「 overshoot」风险。
- 对接受131I治疗或出现甲减的患者,需关注体重增加并加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The most commonly reported symptom of hyperthyroidism is weight loss; successful treatment increases weight. Weight gain faced by patients with hyperthyroidism is widely considered a simple reaccumulation of premorbid weight, whereas many patients feel there is a significant weight "overshoot" attributable to the treatment. We aimed to establish if weight gain seen following treatment for hyperthyroidism represents replenishment of premorbid weight or "overshoot" beyond expected regain and, if there is excessive weight gain, whether this is associated with the applied treatment modality. Methods: We calculated the risk of becoming obese (body mass index [BMI] >30 kg/m2) following treatment for hyperthyroidism by comparing BMI of 1373 patients with overt hyperthyroidism seen in a secondary care setting with the age- and sex-matched background population (Health Survey for England, 2007-2009). Next, we investigated the effect of treatment with an antithyroid drug (ATD) alone in regard to ATD with radioactive iodine (131I) therapy. We modeled the longitudinal weight data in relation to the treatment pathway to thyroid function and the need for long-term thyroxine replacement. Results: During treatment of hyperthyroidism, men gained 8.0 kg (standard deviation ±7.5) and women 5.5 kg (±6.8). At discharge, there was a significantly increased risk of obesity in male (odds ratio = 1.7 [95% confidence interval 1.3-2.2], p < 0.001) and female (1.3, 1.2-1.5, p < 0.001) patients with hyperthyroidism compared with the background population. Treatment with 131I was associated with additional weight gain (0.6 kg, 0.4-0.8, p < 0.001), compared with ATD treatment alone. More weight gain was seen if serum thyrotropin (TSH) was markedly increased (TSH >10 mIU/L; 0.5 kg, 0.3-0.7, p < 0.001) or free thyroxine (fT4) was reduced (fT4 ≤ 10 pmol/L (0.8 ng/dL); 0.3 kg, 0.1-0.4, p < 0.001) during follow-up. Initiation of levothyroxine was associated with further weight gain (0.4 kg, 0.2-0.6, p < 0.001) and the predicted excess weight gain in 131I-induced hypothyroidism was 1.8 kg. Conclusions: Treatment for hyperthyroidism is associated with significant risks of becoming obese. 131I treatment and subsequent development of hypothyroidism were associated with small but significant amounts of excess weight gain compared with ATD alone. We advocate that the discussion over the weight "overshoot" risk forms part of the individualized treatment decision-making process.
引用
- Torlinska B, Nichols L, Mohammed MA, et al. Patients Treated for Hyperthyroidism Are at Increased Risk of Becoming Obese: Findings from a Large Prospective Secondary Care Cohort. Thyroid. 2019. PMID: 31375059. doi:10.1089/thy.2018.0731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。